Josh Jennings: Great. And can we read through that on that commentary that I think you would be reporting value regular users versus centers that, as well as the metric of centers that have enlisted TransMedics and with the NOP service, in the quarter? But did that with capacity expanding that delta and those metrics are just not important. And as you said, not an active predictive growth?
Waleed Hassanein: Exactly. That’s exactly what we are saying, Josh.
Josh Jennings: Excellent. My follow-up is, with something that we talked about, I think at a headquarter visit this quarter, I think, just in my notes, I had you saying that their payers are saving money with NOP cases, and there is a desire from payers for centers to adopt NOP and use TransMedics as that service. I am hoping you could just build on that, and just how much interaction does your company have, should the likes have with payers, and anything you can add just to that, that payers aren’t saving money with each NOP case. Thanks a lot.
Waleed Hassanein: Sure. Thank you, Josh. Let me clarify, Josh’s question. The comments we made during the team from — visit here is absolutely true. What we are referring to is with NOP, the growth of NOP have demonstrated the significant economic benefit of using OCS NOP across that chain of a patient needing an organ transplant, starting with accessing more organ lowers the patient wait time on the waiting list, that’s one of the biggest cost driver to insurance companies, keeping patients on the waiting list in an ICU environment, sometimes even supported, maximum supported in an ICU environment. So that’s number one. Number two, we are seeing the post-transplant surgical procedures that cost add additional costs to the case rate dropping significantly.
For example, post-transplant bleeding, post-transplant take down to the OR, re-transplantation, and post-transplant procedures like ECP is growing down significantly. And that’s what’s causing the payers to say, we are seeing the benefits of it’s really driven by more organs. With more organs, you are really driving the cost efficiency or the health economics of an organ transplant significantly to a transplant pair. And that’s what we are seeing and what we are hearing. We are in constant communication and dialogue with some of the major pairs in the United States. However, we are seeing more and more centers now are picking up that mantle and having their own discussion with their own business cases to their payers, with significant success.
We just held multiple forums here in Boston in mid-October. And many programs highlighted to the rest of the community, their success in growing their transplant volume from OCS and their positive discussion with pairs, commercial pairs, given the significant success they have achieved in growing their volume. So, we continue to believe that, this is going to continue with us. And the key for us is to make sure that, we continue to laser focus on outcomes and the quality of care we are providing. If we do that right, the rest is going to be a pretty straightforward execution challenge.
Operator: The next question comes from Bill Plovanic with Canaccord Ingenuity. Please go ahead.
Bill Plovanic: Actually, I tried to get back out in the queue.
Operator: This concludes our question-and-answer session. I would like to turn the conference over to Waleed Hassanein for any closing remarks.
Waleed Hassanein: Thank you so much for your time this evening, and we’re looking forward to following up and looking forward to our next call. Thank you. Have a great evening everyone.
Operator: The conference is now concluded. Thank you for attending today’s presentation. You may now disconnect.
